Security
CureVac N.V. Ordinary Shares · CVAC
CVACNASDAQCommon stockHistorical · closed Jan 6, 2026CIK 1809122Updated Nov 16, 2026
CVAC price & chart
This listing closed Jan 6, 2026. Live provider charts are shown only for current listings.
About the company
CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. CureVac’s mRNA platform incorporates a series of novel technologies, designed to improve the efficacy, safety and cost-effectiveness of mRNA therapeutics aimed at resulting in enhanced immune responses at lower doses. Additionally, CureVac has developed LNPs, which have been optimized for indication specific use across infectious diseases and oncology. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates. It also develops programs in prophylactic vaccines and in treatments that aim to enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S.
In the news
No coverage from other publishers is available.
Recent filings
Financials
FY 2024 · EURSource
Source
cash flow · annual statements
| Line item | Q4 2024 | Q4 2023 | Q3 2024 | Q3 2023 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Profit or LossEUR | — | — | 338,043,000Source | -48,681,000Source | -59,560,000Source | -72,543,000Source | -52,084,000Source | -70,553,000Source | 162,186,000Source | -260,167,000Source | -249,029,000Source | -411,716,000Source |
| Additional Financial Items | ||||||||||||
| AdjustmentsForCurrentTaxOfPriorPeriodEUR | — | — | — | — | — | — | — | — | -242,000Source | — | — | — |
| AdjustmentsForFinanceCostsEUR | — | — | — | — | — | — | 333,000Source | 340,000Source | 829,000Source | 2,493,000Source | 3,707,000Source | 10,338,000Source |
| AdjustmentsForFinanceIncomeEUR | — | — | — | — | — | — | 3,405,000Source | 3,771,000Source | 14,028,000Source | 16,731,000Source | 4,009,000Source | 10,103,000Source |
| AdjustmentsForSharebasedPaymentsEUR | — | — | — | — | — | — | 1,156,000Source | 487,000Source | 4,121,000Source | 7,697,000Source | 9,185,000Source | 14,956,000Source |
| GeneralAndAdministrativeExpenseEUR | — | — | 16,672,000Source | 18,574,000Source | 25,394,000Source | 15,931,000Source | 16,409,000Source | 19,119,000Source | 69,690,000Source | 91,758,000Source | 104,178,000Source | 100,402,000Source |
| InterestPaidClassifiedAsOperatingActivitiesEUR | — | — | — | — | — | — | 574,000Source | 589,000Source | 2,325,000Source | 2,375,000Source | 4,606,000Source | 9,785,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesEUR | — | — | — | — | — | — | 3,294,000Source | 2,136,000Source | 11,067,000Source | 15,852,000Source | 1,790,000Source | 81,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesEUR | — | — | — | — | — | — | 1,312,000Source | 1,219,000Source | 5,114,000Source | 5,193,000Source | 4,221,000Source | 3,183,000Source |
| ProceedsFromIssuingSharesEUR | — | — | — | — | — | — | — | — | — | 235,840,000Source | — | 404,062,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesEUR | — | — | — | — | — | — | 27,000Source | 14,000Source | 4,129,000Source | 2,880,000Source | 5,199,000Source | 3,679,000Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivities | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2024 | Q4 2023 | Q3 2024 | Q3 2023 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Additional Financial Items | ||||||||||||
| ApplicableTaxRatenumber | — | — | — | — | — | — | — | — | 0.29Source | 0.29Source | 0.29Source | 0.29Source |
| AverageEffectiveTaxRatenumber | — | — | — | — | — | — | — | — | 0.15Source | 0.15Source | — | — |
| BasicEarningsLossPerShareEUR/shares | — | — | 1.51Source | -0.22Source | -0.26Source | -0.32Source | -0.23Source | -0.31Source | 0.72Source | -1.18Source | -1.32Source | -2.21Source |
| CurrentTaxExpenseIncomeEUR | — | — | — | — | — | — | — | — | 19,107,000Source | — | — | — |
| DeferredTaxExpenseIncomeEUR | — | — | — | — | — | — | — | — | 9,588,000Source | 80,000Source | — | — |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossEUR | — | — | — | — | — | — | — | — | -9,588,000Source | -84,000Source | — | — |
| DepreciationAndAmortisationExpenseEUR | — | — | — | — | — | — | 4,577,000Source | 4,867,000Source | 18,809,000Source | — | — | — |
| DepreciationRightofuseAssetsEUR | — | — | — | — | — | — | — | — | 5,136,000Source | 5,772,000Source | 5,053,000Source | 3,901,000Source |
| DilutedEarningsLossPerShareEUR/shares | — | — | 1.5Source | -0.22Source | -0.26Source | -0.32Source | -0.23Source | -0.31Source | 0.72Source | -1.18Source | -1.32Source | -2.21Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesEUR | — | — | — | — | — | — | — | 487,000Source | -4,121,000Source | -7,697,000Source | -9,184,000Source | -14,939,000Source |
| ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsedEUR | — | — | — | — | — | — | — | — | 39,000Source | 55,000Source | 66,000Source | 39,000Source |
| ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedEUR | — | — | — | — | — | — | — | — | 198,000Source | 70,000Source | 76,000Source | 119,000Source |
| FinanceCostsEUR | — | — | 141,000Source | 598,000Source | 565,000Source | 155,000Source | 333,000Source | 340,000Source | 829,000Source | 2,493,000Source | 3,707,000Source | 10,338,000Source |
| FinanceIncomeEUR | — | — | 2,334,000Source | 5,959,000Source | 2,344,000Source | 2,533,000Source | 3,405,000Source | 3,771,000Source | 14,028,000Source | 16,731,000Source | 4,009,000Source | 10,103,000Source |
| GeneralAndAdministrativeExpenseEUR | — | — | 16,672,000Source | 18,574,000Source | 25,394,000Source | 15,931,000Source | 16,409,000Source | 19,119,000Source | 69,690,000Source | 91,758,000Source | 104,178,000Source | 100,402,000Source |
| ImpairmentLossRecognisedInProfitOrLossGoodwillEUR | — | — | — | — | — | — | — | — | — | 0Source | 0Source | — |
| IncomeTaxExpenseContinuingOperationsEUR | — | — | 32,529,000Source | 6,000Source | -406,000Source | 1,301,000Source | 429,000Source | 666,000Source | 28,695,000Source | 198,000Source | -126,000Source | -782,000Source |
| InterestExpenseOnLeaseLiabilitiesEUR | — | — | — | — | — | — | — | — | 2,314,000Source | 2,375,000Source | 2,218,000Source | 1,729,000Source |
| ProfitLossBeforeTaxEUR | — | — | 370,572,000Source | -48,675,000Source | -59,966,000Source | -71,243,000Source | -51,655,000Source | -69,887,000Source | 190,881,000Source | -259,969,000Source | -249,155,000Source | -412,498,000Source |
| ProfitLossFromOperatingActivitiesEUR | — | — | 368,379,000Source | -54,036,000Source | -61,746,000Source | -73,620,000Source | -54,727,000Source | -73,317,000Source | 177,682,000Source | -274,207,000Source | -249,457,000Source | -412,263,000Source |
| ResearchAndDevelopmentExpenseEUR | — | — | 49,979,000Source | 27,245,000Source | 34,879,000Source | 31,093,000Source | 37,593,000Source | 27,825,000Source | 153,034,000Source | 115,724,000Source | 62,550,000Source | 815,907,000Source |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill | — | — | — | — | — | — | — | — | — | — | — | — |
| ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss | — | — | — | — | — | — | — | — | — | — | — | — |